Bioethics Discussion Blog: Good Ethics: FDA Panel Shows Concern for the Patient

REMINDER: I AM POSTING A NEW TOPIC ABOUT ONCE A WEEK OR PERHAPS TWICE A WEEK. HOWEVER, IF YOU DON'T FIND A NEW TOPIC POSTED, THERE ARE AS OF MARCH 2013 OVER 900 TOPIC THREADS TO WHICH YOU CAN READ AND WRITE COMMENTS. I WILL BE AWARE OF EACH COMMENTARY AND MAY COME BACK WITH A REPLY.

TO FIND A TOPIC OF INTEREST TO YOU ON THIS BLOG, SIMPLY TYPE IN THE NAME OR WORDS RELATED TO THE TOPIC IN THE FIELD IN THE LEFT HAND SIDE AT TOP OF THE PAGE AND THEN CLICK ON “SEARCH BLOG”. WITH WELL OVER 900 TOPICS, MOST ABOUT GENERAL OR SPECIFIC ETHICAL ISSUES BUT NOT NECESSARILY RELATED TO ANY SPECIFIC DATE OR EVENT, YOU SHOULD BE ABLE TO FIND WHAT YOU WANT. IF YOU DON’T PLEASE WRITE TO ME ON THE FEEDBACK THREAD OR BY E-MAIL DoktorMo@aol.com

IMPORTANT REQUEST TO ALL WHO COMMENT ON THIS BLOG: ALL COMMENTERS WHO WISH TO SIGN ON AS ANONYMOUS NEVERTHELESS PLEASE SIGN OFF AT THE END OF YOUR COMMENTS WITH A CONSISTENT PSEUDONYM NAME OR SOME INITIALS TO HELP MAINTAIN CONTINUITY AND NOT REQUIRE RESPONDERS TO LOOK UP THE DATE AND TIME OF THE POSTING TO DEFINE WHICH ANONYMOUS SAID WHAT. Thanks. ..Maurice

FEEDBACK,FEEDBACK,FEEDBACK! WRITE YOUR FEEDBACK ABOUT THIS BLOG, WHAT IS GOOD, POOR AND CONSTRUCTIVE SUGGESTIONS FOR IMPROVEMENT TO THIS FEEDBACK THREAD

Friday, January 14, 2005

Good Ethics: FDA Panel Shows Concern for the Patient

Here is an update regarding today's final decision by the FDA panel regarding whether Mevacor should be made an over-the-counter drug as reported by

Bloomberg: "Merck & Co. and Johnson & Johnson shouldn't be allowed to sell their Mevacor cholesterol drug without a doctor's prescription, U.S. government advisers said today, signaling that future applicants need to prove the safety of selling medicines for chronic illnesses over the counter.

A committee of doctors and scientists recommended that the Food and Drug Administration deny the companies' a bid for a nonprescription Mevacor. During a two-day meeting in Bethesda, Maryland, panelists found fault with Merck's research. They said it showed patients would be confused about taking the drug.

``I am concerned that the precedent has really serious ramifications that go beyond this,'' said Nelson Watts, a doctor from Cincinnati who was one of 20 panelists to vote no, against three in favor."

I am pleased that the panel made the right decision and ethically showed beneficence to the public. In view of the ciriticisms the FDA itself is having with regard to other drug issues currently, it is doubtful that the FDA will go against the decision of the panel. ..Maurice.

0 Comments:

Post a Comment

<< Home